galiximab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 458274979

| image =

| type = mab

| mab_type = mab

| source = xi/i

| target = CD80

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 357613-77-5

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = S9OX9692ZB

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D04295

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| chemical_formula =

| molecular_weight =

}}

Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma.{{cite book | vauthors = Ebadi M, Sadeghi MA, Reddy NM, Rezaei N | chapter = Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma | chapter-url = https://books.google.com/books?id=v5AOEAAAQBAJ&dq=Galiximab&pg=PA178 | page = 178 | veditors = Rezaei M|title=Cancer immunology: cancer immunotherapy for organ-specific tumors |date=2020 |location=Cham | publisher = Springer Nature |isbn=978-3-03-057949-4 |edition=Second}} {{As of|September 2009}}, it is undergoing Phase III clinical trials.{{Cite web |url=http://www.biogenidec.com/site/pipeline.html |title=Biogen Idec: Pipeline |access-date=2009-09-24 |archive-url=https://web.archive.org/web/20080517130617/http://www.biogenidec.com/site/pipeline.html |archive-date=2008-05-17 |url-status=dead }} The drug is a chimeric antibody from Macaca irus and Homo sapiens.[https://web.archive.org/web/20091016222527/http://whqlibdoc.who.int/druginfo/INN_2004_list51.pdf WHO Drug Information]